We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Antibodies in Llama Blood Could Hold Key to Developing COVID-19 Vaccine

By HospiMedica International staff writers
Posted on 23 Apr 2020
Researchers from the Vlaams Institute for Biotechnology {(VIB) Ghent, Belgium} have proposed that antibodies found in the blood of the South American animal, llamas could hold the key to developing a vaccine for COVID-19. More...
The researchers discovered the llama antibodies while previously researching HIV and believe that they could help to neutralize SARS-CoV-2 that causes COVID-19.

The antibodies found in llama blood are smaller than human antibodies, but have shown to be effective against MERS and SARS, which are close relatives of the novel coronavirus that causes COVID-19. This could make it possible to use the animal-based antibodies in nanotechnology as part of a delivery of antiviral activity into humans. American researchers have earlier used llama antibodies for developing a universal flu vaccine and discovered that they work effectively on a variety of flu viruses.

In addition to focusing on the llama, researchers across the world are also looking at ferrets and hamsters for a COVID-19vaccine candidate. For instance, South Korean researchers using ferrets as animal models for testing potential COVID-19 drugs in humans have found that the disease behaves in the same way in ferrets as it does in humans. The researchers found ferrets to be good candidates for research because the anatomic proportions of the ferret’s upper and lower respiratory tracts, the density of submucosal glands in the bronchial wall and the number of generations of terminal bronchioles reproduce the condition in the human respiratory tract. Similarly, researchers in Hong Kong experienced success with Syrian hamsters after their studies showed that hamsters displayed similar effects of the COVID-19 disease.

Despite the best efforts by researchers across the world for developing a COVID-19 vaccine candidate, data indicates that a vaccine will be unavailable for use until the end of 2020 or early 2021.

Related Links:
Vlaams Institute for Biotechnology


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Infant Resuscitator
Easypuff
Morcellator
TCM 3000 BL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.